Determination of Th9 cells and IL-9 in children with Mycoplasma pneumoniae infection

WANG Jian-Yong; ZHENG Jing; XING Hai-Yan; JIA Xiu-Hong

doi:10.7499/j.issn.1008-8830.2015.04.003

PDF(1234 KB)

Chinese Journal of Contemporary Pediatrics ›› 2015, Vol. 17 ›› Issue (4) : 308-311. DOI: 10.7499/j.issn.1008-8830.2015.04.003

CLINICAL RESEARCH

Determination of Th9 cells and IL-9 in children with Mycoplasma pneumoniae infection

WANG Jian-Yong¹, ZHENG Jing², XING Hai-Yan³, JIA Xiu-Hong¹

Author information +

History +

Abstract

Objective To investigate the clinical significance of T helper type 9 (Th9) cells and interleukin-9 (IL- 9) in children suffering from Mycoplasma pneumoniae (MP) infection. Methods A total of 86 children who were diagnosed with MP infection between January 2013 and June 2014 were classified into upper respiratory infection (URI) group (n=29), mild MP pneumonia (MPP) group (n=32) and severe MPP group (n=25). Twenty-eight healthy children were used as the control group. Peripheral blood mononuclear cells were isolated by Ficoll density gradient centrifugation, and the percentage of Th9 cells in peripheral blood was measured by flow cytometry. Serum IL-9 level was determined using ELISA. Results The URI, mild MPP, and severe MPP groups had significantly higher percentages of Th9 cells and IL-9 levels than the control group (P<0.05); the mild MPP and severe MPP groups had significantly higher percentages of Th9 cells and IL-9 levels than the URI group (P<0.05), and the two indices were significantly higher in the severe MPP group than in the mild MPP group (P<0.01). Conclusions Children with MP infection have an elevated percentage of Th9 cells and IL-9 expression, both of which are positively correlated with the severity of the disease. It can be predicted that Th9 cells and IL-9 can be used as evaluation indicators for the progression and outcome of children with MP infection.

Key words

Mycoplasma pneumoniae / T helper type 9 cell / Interleukin-9 / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

WANG Jian-Yong, ZHENG Jing, XING Hai-Yan, JIA Xiu-Hong. Determination of Th9 cells and IL-9 in children with Mycoplasma pneumoniae infection[J]. Chinese Journal of Contemporary Pediatrics. 2015, 17(4): 308-311 https://doi.org/10.7499/j.issn.1008-8830.2015.04.003

References

[1] Cao B, Ren LL, Zhao F, et al. Viral and Mycoplasma pneumonia community-acquired pneumonia and novel clinical outcome evaluation in ambulatory adult patients in China[J]. Eur J Clin Microbiol Infect Dis, 2010, 29(11): 1443-1448.
[2] Veldhoen M, Uyttenhove C, Van Snick J, et al. Transforming growth factor-beta ‘reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset[J]. Nat Immunol, 2008, 9(12): 1341-1346.
[3] 胡亚美, 江载芳. 诸福棠实用儿科学[M]. 第7 版. 北京: 人民卫生出版社, 2003: 1204-1205.
[4] 齐建光, 张韶杰, 陈永红, 等. 儿童重症支原体肺炎的临床特征和治疗探讨[J]. 中国当代儿科杂志, 2008, 10(6): 719- 722.
[5] Bae JW, Kim HJ, Chang GY, et al. Combined striatum, brain stem, and optic nerve involvement due to Mycoplasma pneumoniae in an ambulatory child[J]. Case Rep Neurol, 2011, 3(2): 109-112.
[6] Yang J, Hooper WC, Phillips DJ, et al. Cytokines in Mycoplasma pneumoniae infections[J]. Cytokine Growth Factor Rev, 2004, 15(2-3): 157-168.
[7] 潘薇, 许忠, 郑百红. 肺炎支原体肺炎患儿急性期外周血 IFN-γ、IL-4 的变化[J]. 中国当代儿科杂志, 2006, 8(5): 373- 375.
[8] 宋磊, 赵小冬, 张瑜, 等. 儿童肺炎支原体感染者血Th17/Treg 的变化分析与临床意义[J]. 中国血液流变学杂志, 2011, 21(4): 699-702.
[9] Dardalhon V, Awasthi A, Kwon H, et al. IL-4 inhibits TGF-betainduced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells[J]. Nat Immunol, 2008, 9(12): 1347-1355.
[10] Li Z, Zhang Y, Sun B. Current understanding of Th2 cell differentiation and function[J]. Protein Cell, 2011, 2(8): 604- 611.
[11] Wiener Z, Falus A, Toth S. IL-9 increases the expression of several cytokines in activated mast cells, while the IL-9-induced IL-9 production is inhibited in mast cells of histamine-free transgenic mice[J]. Cytokine, 2004, 26(3): 122-130.
[12] Xing J, Wu Y, Ni B. Th9: a new player in asthma pathogenesis?[J]. J Asthma, 2011, 48(2): 115-125.
[13] Ciprandi G, De Amici M, Marseglia GL. Serum IL-9 levels and sublingual immunotherapy: preliminary report[J]. J Biol Regul Homeost Agents, 2011, 25(2): 295-297.
[14] Devos S, Cormont F, Vrtala S, et al. Allergen-induced interleukin-9 production in vitro: correlation with atopy in human adults and comparison with interleukin-5 and interleukin- 13[J]. Clin Exp Allergy, 2006, 36(2): 174-182.
[15] 崔冉, 徐建华. 类风湿关节炎患者外周血辅助性T 细胞9 及白细胞介素-9 的变化及临床意义[J]. 中华风湿病性杂志, 2012, 16(7): 442-445.
[16] Yanaba K, Yoshizaki A, Asano Y, et al. Serum interleukin 9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis[J]. J Rheumatol, 2011, 38(10): 2193-2197.
[17] Parker JM, Oh CK, LaForce C, et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma[J]. BMC Pulm Med, 2011, 11: 14.